This inventor holds 1 USPTO granted patent. Top assignees: Alexion Pharmaceuticals, Inc., National Institute of Health and Medical Research. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2026
Title: Marion Delous: Innovator in Ciliopathy Treatment
Introduction
Marion Delous is a notable inventor based in Lyon, France. He has made significant contributions to the field of medicine, particularly in the treatment of diseases associated with ciliopathies. His innovative approaches have the potential to improve the lives of many individuals affected by these conditions.
Latest Patents
Delous holds a patent for "Methods for treating diseases associated with ciliopathies." This patent discloses methods of treating a ciliopathy-associated disease by administering an effective amount of a compound that targets at least one G-protein coupled receptor. Additionally, it provides methods for identifying therapeutic agents for treating diseases related to ciliopathies. This includes using an animal model system to test potential therapeutic agents and comparing the measurable phenotypes of treated and untreated animals.
Career Highlights
Throughout his career, Marion Delous has worked with prominent organizations such as Alexion Pharmaceuticals, Inc. and the National Institute of Health and Medical Research. His experience in these institutions has allowed him to develop and refine his innovative methods for treating ciliopathies.
Collaborations
Delous has collaborated with several professionals in his field, including Sophie Saunier and Luis Briseno-Roa. These collaborations have contributed to the advancement of research and development in the treatment of ciliopathy-associated diseases.
Conclusion
Marion Delous is a pioneering inventor whose work in treating ciliopathies showcases the importance of innovation in medicine. His contributions have the potential to lead to significant advancements in therapeutic approaches for these complex diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile